Novartis AG (NYSE:NVS) has reportedly built up its pharmaceutical stockpiles in the U.S. as a cushion against the potential impact of tariffs under consideration by the Trump administration, chief executive Vas Narasimhan said in a recent interview.
Currently, U.S. tariffs do not apply to pharmaceuticals, despite the 39% levy Washington imposed on Swiss imports last month. However, the industry is watching closely as an investigation could still lead to sector-specific duties.
